NCT05701644View on ClinicalTrials.gov

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

June 28, 2023

Study Completion Date

June 28, 2023

Conditions
Healthy
Interventions
DRUG

C1K 150mg

Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15

DRUG

C1K 300mg

Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15

DRUG

Placebo with the same volume of C1K 300mg

Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15

DRUG

C1K 600mg

Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15

DRUG

Placebo with the same volume of C1K 600mg

Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15

DRUG

C1K 900mg

Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15

DRUG

Placebo with the same volume of C1K 900mg

Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15

DRUG

C1K 1200mg

Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15

DRUG

Placebo with the same volume of C1K 1200mg

Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Ensol Bioscience
All Listed Sponsors
lead

Ensol Bioscience

INDUSTRY

NCT05701644 - Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects | Biotech Hunter | Biotech Hunter